Exactly! That's what makes IsoPet so powerful right now....it’s growing fast, clinics are lining up, and RDGL is investing heavily to expand it rather than worrying about short-term profit. You basically explained why it’s working.
Early-stage medical tech always scales at cost. That’s how you seed the market, build adoption, and lock in future revenue streams.
So yeah… thank you for pointing out how aggressively IsoPet is expanding. Couldn't have said it better myself.
And calling it a “distraction”?
Totally agree..... it’s distracting everyone with steady growth, more treatments, and a bigger presence every year. Hard to ignore success like that.
Appreciate you highlighting all the momentum again. Keep it coming!
$RDGL